Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LB-100

Small molecule · Inhibitor of protein phosphatase 2A (PPP2CA) · developed by Lixte Biotechnology Holdings

Phase 1/2 Most advanced trial
1 Registered trials

What is LB-100?

LB-100 is a water-soluble inhibitor of protein phosphatase 2A (PP2A), a serine/threonine phosphatase involved in cell growth control and DNA damage repair. It is studied in combination with chemotherapy or radiotherapy in ovarian clear cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
protein phosphatase 2A (PPP2CA)
Mechanism
Inhibitor of protein phosphatase 2A (PPP2CA)
Pathways
cell cycle progression, DNA damage repair
Therapy area
Oncology
Developer
Lixte Biotechnology Holdings, Inc.
In trials of
GSK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
0C1JUU9S0L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06065462 Phase 1/2 Ovarian Clear Cell Carcinoma Recruiting GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Clear Cell Carcinoma

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.